GSK Boosts Theravance, Near-Term
We expect the U.S. launch of Theravance, Inc.'s (THRX) Telavancin, for the treatment of complicated skin infections, to occur by August, provided the company satisfactorily deals with the manufacturing issues and site monitoring and conduct concerns raised by the U.S. Food and Drug Administration. However, given the stiff competition in the complicated skin and skin structure infections and the hospital-acquired pneumonia markets, we expect only $185 million in Telavancin sales in 2011.
The company's new financial restructuring program will result in annual cost savings of $17 million. However, we are more excited about the company's Beyond Advair collaboration with
GlaxoSmithKline (GSK). The deal holds significant value for the company and could eventually drive the company to profitability.
Theravance has a deep pipeline of exciting, late-stage compounds. However, approval of one or more of the compounds under the collaboration is not expected before 2011. Hence, we maintain our Hold rating on Theravance. We arrive at our target price of $15 by applying a P/S multiple of 15.4x to our 2011 revenue figure of $105.2 million, discounted at 20 percent for 3 years.
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
